Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

British researchers are zeroing in on genes they believe are responsible for early onset Alzheimer’s disease in people with Down syndrome.

WEDNESDAY, July 3, 2018 — British researchers are zeroing in on the genes that they believe are responsible for early onset Alzheimer’s disease in people with Down syndrome.

The two conditions have long been strongly linked.

The findings — based on research with mice — could pave the way for new medicines to prevent Alzheimer’s in people with Down syndrome, and shed light on the development of dementia in the general population, the study authors said.

Read more

Following heart attacks, a handful of monkeys regained some of the pumping ability their hearts had lost after being given human embryonic stem cells, according to a study published Monday in Nature Biotechnology.

Scientists have tried for years to develop a stem cell treatment for heart disease caused by lack of blood flow, which contributed to more than 9.4 million deaths worldwide in 2016, according to the World Health Organization.

“We’re talking about the number one cause of death in the world [for humans],” said study author Dr. Charles Murry, director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. “And at the moment all of our treatments are … dancing around the root problem, which is that you don’t have enough muscle cells.”

Read more

“I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses,” said FDA commissioner Dr Scott Gottlieb after Luxturna’s approval.

As innovative gene and cell therapies continue to make the transition from the laboratory to the clinic, they are bringing with them the promise of truly personalised medicine. The last few years have seen the regulatory approval of the first gene therapies that take a patient’s own immune cells and genetically engineer them to target cancer cells more effectively.

These chimeric antigen receptor T-cell (CAR-T) therapies now represent a rapidly growing field, with Novartis’s Kymriah, the first CAR-T therapy approved by the US Food and Drug Administration (FDA) in August 2017 for the treatment of a rare blood cancer, seen as the tip of the iceberg for this treatment class’ potential. Approval of Kite Pharma’s Yescarta, a CAR-T treatment for certain forms of non-Hodgkin lymphoma, followed just a few months later.

Read more

Scientists have designed a special type of drug that helps the body eat and destroy cancerous cells.

The treatment boosts the action of white blood cells, called macrophages, that the immune system uses to gobble up unwanted invaders.

Tests in mice showed the therapy worked for aggressive breast and skin tumours, Nature Biomedical Engineering journal reports.

Read more

The next phase of a NASA sponsored mission to 3D print human organs and tissues in space will launch in February 2019. A 3D BioFabrication Facility (BFF) developed by nScrypt and Techshot and destined for the International Space Station (ISS) will form part of the cargo of SpaceX CRS-17.

3D printing in zero gravity

nScrypt is based in Orlando, Florida and is a manufacturer of industrial micro-dispensing and 3D printing systems. The company is spin out of Sciperio Inc who, under a DARPA contact, developed an award winning bioprinter in 2003.

Read more

Monsanto’s agricultural biotechnology research and development operations that are going to Bayer are the largest in the world and include making genetically modified seeds for such crops as corn, soybeans and cotton. Corn represented almost 60 percent of Monsanto’s total seed and genomics business last year.

German conglomerate Bayer on Thursday closed its $63 billion merger with St. Louis-based agribusiness giant Monsanto and plans to drop the U.S. company’s name.

Read more

(HealthDay)—Get up off of the couch: Sitting too much may kill you even if you exercise regularly.

If you sit for six hours a day or more, your risk of dying early jumps 19 percent, compared with people who sit fewer than three hours, an American Cancer Society study suggests.

And, the study authors added, sitting may kill you in 14 ways, including: cancer; heart disease; stroke; diabetes; kidney disease; suicide; chronic (COPD); lung disease; liver disease; peptic ulcer and other ; Parkinson’s disease; Alzheimer’s disease; nervous disorders; and .

Read more

Researchers at the University of Alabama at Birmingham have shown—for the first time—that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.

This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent , effective treatment interventions are lacking.

Pulmonary fibrosis can develop after injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in , or IPF is a progressive, and ultimately fatal, that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.

Read more